Home   HELP  /   AYUDA  /   求助 : help-desk@bctrials.org  /   (415) 476-5777 Click to print page  Print

Browse Trials


In response to COVID-19, some breast cancer trials have temporarily stopped enrolling new patients. Use the contact information in our trial listings to call or email the research site for information about a trial's status.

Visit COVID-19 & Cancer Clinical Trials on Metastatic Trial Talk for regularly updated information about clinical trials during the coronavirus pandemic.


Currently viewing trials
(Last updated: July 07, 2020)

Zip Code:
 

Narrow my choices:

Radius (miles): All U.S.

20 All U.S.
Early stage    Advanced 
Treatment    Non-treatment 
Phase    I     II     III 
Display Only New Trials 
 
Close
Treatment

BRCA1/2

Chemotherapy

Hormone Therapy

Radiation Oncology

Surgery

Surgery: Reconstruction

Targeted Therapy: All

Targeted Therapy: Anti-HER2 Therapy

Targeted Therapy: CDK Inhibitors

Targeted Therapy: PARP Inhibitors

Targeted Therapy: Tumor Mutations

Targeted Therapy: Other Targeted Therapy

Vaccines and Immunotherapy

Other Treatment

Non-Treatment

Activities

Complementary and Alternative Medicine

Decision Support

Diagnosing Breast Cancer

Genetics/Family History

Having Children

Lymphedema

Managing Side Effects

No Travel Required

Predicting Response to Treatment

Preventing Breast Cancer

Preventing Recurrence

Screening

Support/Education

Surveys/Interviews/Registries

1

NEAREST SITE: 3 miles
UCSF Helen Diller Family Comprehensive Cancer Center
San Francisco,CA

VISITS: 2 visits every 3 weeks; or coincides with chemotherapy treatment

PHASE: III

NCT ID: NCT03901339

Sacituzumab Govitecan in Advanced Hormone Positive, HER2 Negative Breast Cancer (TROPICS-02)

Phase 3 Study of Sacituzumab Govitecan vs Physician's Choice in Subjects With Hormonal Receptor-Positive Human Epidermal Growth Factor Receptor 2 Negative Metastatic Breast Cancer Who Have Failed at Least 2 Prior Chemotherapy Regimens Scientific Title

Purpose
To compare the safety and effects (good and bad) of sacituzumab govitecan to standard of care chemotherapy.
Who is this for?
People with metastatic (stage IV) hormone positive (ER+ and/or PR+), HER2 negative (HER2-) breast cancer that has already been treated with 2 to 4 different chemotherapy regimens.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will be randomly assigned to 1 of 2 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1: Experimental</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem"><span class="highlight">Sacituzumab</span> <span class="highlight">Govitecan</span> (IMMU-132), by IV, 2 times every 3 weeks</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2: Standard of care</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Chemotherapy (eribulin, capecitabine, gemcitabine, or vinorelbine), determined by your physician</li></ul>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">The investigational chemotherapy is called <span class="highlight">sacituzumab</span> <span class="highlight">govitecan</span> (IMMU-132). </li> <li class="seamTextUnorderedListItem">It is approved for use in some people with metastatic (stage IV) triple negative (ER-, PR-, HER2-) breast cancer.</li> <li class="seamTextUnorderedListItem">It is an antibody-drug conjugate (ADC). This means it uses an antibody that targets cancer cells to deliver a chemotherapy drug directly to these cells. </li> <li class="seamTextUnorderedListItem">The antibody in this drug targets TROP2 proteins. </li> <li class="seamTextUnorderedListItem">It delivers the chemotherapy drug SN-38.</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03901339' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.org/latest-news/fda-approves-trodelvy-sacituzumab-govitecan-hziy-for-triple-negative-breast-cancer.html' target='_blank'>American Cancer Society: FDA Approves Trodelvy (Sacituzumab Govitecan-Hziy) for Triple Negative Breast Cancer</a> </li><li class='seamTextUnorderedListItem'><a href='https://metastatictrialtalk.org/2019/05/01/mbc-news-11/' target='_blank'>MetastaticTrialTalk: Getting to the Target, Antibody Drug Conjugates in Breast Cancer</a> </li></ul>
See more
2

NEAREST SITE: 1481 miles
Mays Cancer Center, UT Health San Antonio
San Antonio,TX

VISITS: 2 visits every 3 weeks, ongoing

PHASE: NA

NCT ID: NCT03995706

A Targeted Therapy for Breast Cancer That Has Spread to the Brain

A Phase 0, Investigator Initiated Study to Determine the Bioavailability of Sacituzumab Govitecan in Breast Brain Metastasis and Glioblastoma Scientific Title

Purpose
To look at the safety of sacituzumab govitecan, an antibody-drug conjugate.
Who is this for?
People with metastatic (stage IV) breast cancer that has spread to the brain and scheduled to have surgery to remove the tumors in your brain.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem"><span class="highlight">Sacituzumab</span> <span class="highlight">govitecan</span>, by IV, 1 day before surgery, then 2 times every 3 weeks following surgery, ongoing</li></ul>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem"><span class="highlight">Sacituzumab</span> <span class="highlight">govitecan</span> is an antibody-drug conjugate (ADC). </li> <li class="seamTextUnorderedListItem">These drugs combine an antibody that can target a cancer cell with an anti-cancer drug. </li> <li class="seamTextUnorderedListItem">The anti-cancer drug in <span class="highlight">sacituzumab</span> <span class="highlight">govitecan</span> is irinotecan, a chemotherapy drug used to treat many types of cancer.</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03995706' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://en.wikipedia.org/wiki/Sacituzumab_govitecan' target='_blank'>Wikipedia: Sacituzumab Govitecan</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancertodaymag.org/pages/Fall2015/Advances-Treating-Brain-Metastases.aspx' target='_blank'>Cancer Today: Breaking the Blood-Brain Barrier</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.nejm.org/doi/full/10.1056/NEJMoa1814213' target='_blank'>The New England Journal of Medicine: Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer</a> </li></ul>
See more
3

NEAREST SITE: 1643 miles
MD Anderson Cancer Center
Houston,TX

VISITS: 2 visits every 3 weeks, ongoing

PHASE: I-II

NCT ID: NCT03992131

Rubraca & Sacituzumab Govitecan to Treat Metastatic Triple Negative or BRCA+ Tumors

SEASTAR: A Phase 1b/2, Open-label, Parallel Arm Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Oral Rucaparib in Combination With Other Anticancer Agents in Patients With a Solid Tumor Scientific Title

Purpose
To study the safety and effects (good and bad) of the combination of rucaparib (Rubraca®) and sacituzumab govitecan.
Who is this for?
People with metastatic (stage IV) triple negative (ER-, PR- and HER2-) breast cancer that has been treated with at least one standard therapy.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Rucaparib (Rubraca®), by mouth, twice daily, ongoing</li> <li class="seamTextUnorderedListItem"><span class="highlight">Sacituzumab</span> <span class="highlight">govitecan</span> (IMMU-132), by IV, 2 times every 3 weeks, ongoing</li></ul>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Rubraca is a PARP inhibitor approved to treat recurrent ovarian, fallopian tube, and primary peritoneal cancer. </li> <li class="seamTextUnorderedListItem"><span class="highlight">Sacituzumab</span> <span class="highlight">govitecan</span> is a type of cancer therapy called an antibody-drug conjugate. It uses an antibody that targets cancer cells to deliver the drug SN-38 directly to these cells.</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03992131' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/publications/dictionaries/cancer-drug/def/rucaparib-phosphate' target='_blank'>NCI Drug Dictionary: Rucaparib</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.clovisoncology.com/pipeline/rucaparib/' target='_blank'>Drug company information site: Rucaparib</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/publications/dictionaries/cancer-drug/def/sacituzumab-govitecan' target='_blank'>NCI Drug Dictionary: Sacituzumab govitecan</a> </li></ul>
See more
4

NEAREST SITE: 2693 miles
Massachusetts General Hospital Cancer Center
Boston,MA

VISITS: Weekly visits for 2 out of every 3 weeks

PHASE: I-II

NCT ID: NCT04039230

Sacituzumab Govitecan and Talazoparib for Women With Metastatic Triple Negative Breast Cancer

Phase 1b/2 Study to Evaluate Antibody-Drug Conjugate Sacituzumab Govitecan in Combination With PARP Inhibitor Talazoparib in Patients With Metastatic Breast Cancer Scientific Title

Purpose
To evaluate the safety, best dose, and effects (good and bad) of using a PARP inhibitor in combination with sacituzumab govitecan.
Who is this for?
Women with metastatic (stage IV) triple negative (ER-, PR-, HER2-) breast cancer.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Talazoparib (Talzenna®), by mouth, daily, ongoing</li> <li class="seamTextUnorderedListItem"><span class="highlight">Sacituzumab</span> <span class="highlight">govitecan</span> (IMMU-132), by IV, once a week, for 2 out of every 3 weeks, ongoing</li></ul>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">The PARP inhibitor being used in this study is talazoparib (Talzenna®). It is approved for use in individuals with advanced triple negative breast cancer and an inherited BRCA 1 or BRCA 2 mutation. </li> <li class="seamTextUnorderedListItem"><span class="highlight">Sacituzumab</span> <span class="highlight">govitecan</span> (IMMU-132) has been approved for use in some metastatic triple negative breast cancer. </li> <li class="seamTextUnorderedListItem"><span class="highlight">Sacituzumab</span> <span class="highlight">govitecan</span> is an antibody-drug conjugate (ADC). This type of drug uses an antibody that targets cancer cells to deliver a chemotherapy drug directly to these cells. </li> <li class="seamTextUnorderedListItem">The antibody in this drug targets TROP2 proteins. It delivers the chemotherapy drug SN-38.</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04039230' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/publications/dictionaries/cancer-drug/def/sacituzumab-govitecan' target='_blank'>NCI Drug Dictionary: Sacituzumab Govitecan</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.ascopost.com/news/april-2020/fda-approves-sacituzumab-govitecan-hziy-for-patients-with-previously-treated-metastatic-triple-negative-breast-cancer/' target='_blank'>ASCO: FDA Approves Sacituzumab Govitecan-hziy for Patients With Previously Treated Metastatic Triple-Negative Breast Cancer</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.immunomedics.com/sacituzumab-govitecan-immu-132/' target='_blank'>Drug Company Information Page: Sacituzumab Govitecan</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.talzenna.com/?source=google&HBX_PK=s_talazoparib&skwid=43700039109819878' target='_blank'>Pfizer Oncology: Talzenna™</a> </li><li class='seamTextUnorderedListItem'><a href='https://metastatictrialtalk.org/2019/05/01/mbc-news-11/' target='_blank'>Metastatic Trial Talk: ADCs in Breast Cancer</a> </li></ul>
See more